Singapore Liver Cancer Therapeutics Market Report 2022 to 2030

Singapore Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Singapore Liver Cancer Therapeutics market will reach a value of $13.4 Mn from $3.52 Mn in 2022, growing at a CAGR of 18.2 % during 2022-2030. The Liver Cancer Therapeutics in Singapore is dominated by a few domestic pharmaceutical companies such as Clearbridge BioMedics, A*STAR and ASLAN Pharmaceuticals. The Liver Cancer Therapeutics market in Singapore is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Singapore Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10SGPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Dr. Vishwa Modhia

Buy Now

Singapore Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Singapore Liver Cancer Therapeutics market will reach a value of $13.4 Mn from $3.52 Mn in 2022, growing at a CAGR of 18.2 % during 2022-2030.

Singapore is a high-income, developing island country off the southern tip of the Malay Peninsula in Southeast Asia. According to WHO, the predicted number of new liver cancer cases in Singapore in 2020 attributed to alcohol consumption was 33% of all cancers. According to the most recent WHO data, 746 people died from liver cancer in Singapore in 2020, accounting for 3.14 % of all deaths. Singapore ranks 46th in the world in terms of age-adjusted death rate (8.32 per 100,000 population). After breast, colorectal, and lung cancer, liver cancer is the fourth most frequent cancer in Singapore. In Singapore, there were 1,056 new cases of liver cancer in 2019.

Surgery, chemotherapy, and radiation therapy are all possibilities for treating liver cancer in Singapore. Immunotherapies and targeted medicines are also becoming more widely available. Singapore's government spent 6.1 % of its GDP on healthcare in 2020. Local pharmaceutical companies in Singapore, such as ASLAN Pharmaceuticals and ImmuneMed, are developing and testing new liver cancer drugs. International pharmaceutical companies, such as Bayer and Bristol Myers Squibb, also operate in the Singapore market.

Singapore Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The incidence of liver cancer in Singapore has increased over the last few decades, with men aged 50 and older having the highest incidence rates. Precision medicine, or tailoring treatments to individual patients based on genetic makeup and other characteristics, is becoming increasingly significant in the treatment of liver cancer. This is increasing demand for new medications and diagnostic tests that can assist in determining the most effective therapies for particular patients. Singapore's advantageous location as a pharmaceutical and biotech hub has attracted major investment in the treatment sector. These aspects could boost the Singapore Liver Cancer Therapeutics market.

Market Restraints

While Singapore's pharmaceutical regulatory environment is usually regarded as favourable to innovation, the country's Health Sciences Authority (HSA) maintains stringent conditions for the clearance of new products. In Singapore, the five-year survival rate for liver cancer is roughly 20%. This is due in part to the fact that liver cancer is frequently not detected until it is advanced. Singapore faces challenges such as a shortage of trained labour and housing, as well as an ageing population. It relies largely on exports and imports. These factors may deter new entrants into the Singapore Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

ASLAN Pharmaceuticals: ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company that is developing a pipeline of oncology therapeutics, including a candidate for the treatment of liver cancer
A*STAR's Experimental Therapeutics Centre (ETC): ETC is a Singapore-based research centre that is focused on the discovery and development of new therapeutics for a range of diseases, including cancer
Clearbridge BioMedics: Clearbridge BioMedics is a Singapore-based company that develops and commercializes medical devices for cancer diagnosis and treatment. The company's flagship product, the ClearCell FX System, is a label-free liquid biopsy platform that enables the isolation and analysis of circulating tumour cells from patient blood samples
Duke-NUS Medical School: Duke-NUS Medical School is a Singapore-based medical school that conducts research in a range of areas, including cancer biology and therapeutics

Recent Notable updates

March 2023: Cancer Research Horizons, the innovation engine at the heart of Cancer Research UK, and the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology, and Research (A*STAR), announced a 5-year collaboration. Under the terms of the Memorandum of Understanding, both parties will investigate collaborations to advance their mutual goals of expediting the translation of cancer research into better treatments for cancer patients.

Healthcare Policies and Reimbursement Scenarios

In Singapore, the regulation and reimbursement of liver cancer therapeutics are governed by the Health Sciences Authority (HSA) and the Ministry of Health (MOH), respectively. In Singapore, the MOH manages the country's healthcare system and is responsible for determining which healthcare services and treatments are covered by the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.